Navigation Links
U-M researchers advocate national strategic approach to therapeutic cancer vaccines
Date:6/8/2011

ANN ARBOR, Mich. Vaccines that save lives by preventing disease have been around for centuries. Now, new vaccines that treat cancer are being developed, but how they will be combined with existing treatments is not clear.

Researchers at the University of Michigan Health System recommend that a national strategy be developed for bringing therapeutic cancer vaccines to patient care, so that cancers with less effective treatment options are priority targets.

"Vaccines that prevent disease have profoundly changed the lives of billions of people around the world," says Matthew M. Davis, M.D., MAPP, associate professor of pediatrics and internal medicine at the University of Michigan Medical School. "A national strategy for therapeutic cancer vaccines would help emphasize development and regulatory approval for vaccines targeting cancers that currently do not have other good therapeutic options."

Davis and co-author Elias J. Dayoub, a student at the U-M Medical School, published a commentary in the June 8 theme issue on cancer of the Journal of the American Medical Association.

When germs such as viruses or bacteria enter the body, the human immune system recognizes those germs as something abnormal and attacks them. Preventive vaccines use this natural response to prime the body's immune system so it can respond to bacteria such as pertussis (the cause of whooping cough) or viruses such as polio and measles.

With cancer cells, however, it is hard for the immune system to detect the "invaders," since they are the human body's own cells gone bad. Therapeutic cancer vaccines can enable the immune system to recognize undetected harmful cells and generate a response to fight back.

Lung cancer, pancreatic cancer and types of leukemia's all have lower survival rates than many other cancers because they respond poorly to currently available chemotherapy, radiation and surgery.

More than 200,000 Americans died from these cancers in 2010more deaths than from breast, prostate and colon cancer combined. Davis suggests that therapeutic vaccines can be used to improve the survival rates of patients with leukemia, lung cancer and pancreatic cancer and also for less common tumors that have similarly poor survival rates.

In 2010, the first cancer therapeutic vaccine was approved for specific forms of prostate cancer. Davis calls it "a major milestone for the entire class of therapeutic cancer vaccines in the United States."

Current research suggests it may be easier for scientists to develop specific vaccines, but Davis emphasizes that what is scientifically easiest may not necessarily benefit the broadest and largest groups of patients.

"While pharmaceutical research and development clearly can lead to exciting advances in care, it may take a strategic plan to help channel creative energy and effort into certain products that maximize benefit for the greatest number of patients over the shortest time frame," says Davis.

A strategic plan could include targeted funding for research and clinical trials that test specific vaccine candidates, explains Davis.

With currently available treatments, two out of every three people in the United States who are diagnosed with cancer survive for at least five years, according to the National Cancer Institute. Complications from these treatments can reduce patients' quality of life, though. Vaccines may potentially offer fewer side effects.

"While it is too early to claim success for therapeutic cancer vaccines, they offer patients and families facing cancer a new ray of hope," concludes Davis.


'/>"/>

Contact: Imran Hyder
imranh@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals
2. Researchers discover biochemical weakness of malaria parasite -- vaccine to be developed
3. Researchers find that inhibiting microRNAs may help prevent degenerative eye disorders
4. Calorie-burning brown fat is a potential obesity treatment, researchers say
5. City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO
6. U of Alberta researchers hoping to stop heart disease in cancer patients before it starts
7. U of A researchers hope to stop heart
8. UofL researchers uncover mechanism in saliva production
9. UF researchers suggest cholera vaccination strategies for Zimbabwe
10. Researchers characterize epigenetic fingerprint of 1,628 people
11. Researchers develop strategy to improve patient adherence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: